The company’s nine-valent HPV vaccine phase III clinical research is ongoing
September 24, 2025
Source: drugdu
161
Watson Bio（300142. SZ) said on the investor interactive platform on September 24 that the relevant work of the company's nine-valent HPV vaccine phase III clinical research is continuing, and if there is substantial and phased progress in the research and development of the company's developing vaccine, the company will disclose it in a timely manner, and please pay attention to the relevant information disclosed by the company for the follow-up progress.
https://finance.eastmoney.com/a/202509243522306220.html
Copyright©2025 Ddu. All rights reserved.
Read more on
- Multiple batches of quadrivalent influenza virus split vaccine have been sub-packaged and submitted for lot release approval; expected to be released to the market soon after approval December 12, 2025
- Ab&B Bio-Tech CO., LTD. JS Lyophilized Human Rabies Vaccine Initiates Phase III Clinical Trials December 12, 2025
- The ‘Sweetest’ HPV Vaccine Market is Gone | Haibin Interview December 12, 2025
- InnoCare Pharma announced that its first independently developed next-generation TRK inhibitor, zoletrazinib, has been approved for marketing in China December 12, 2025
- Is PD-1/VEGF dual antibody + ADC becoming the standard configuration? December 12, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
